Actualizado 09/12/2009 10:08
- Comunicado -

Important Progress in Treatment of Early and Late Stage Breast Cancer With Herceptin, Avastin and T-DM1 (y 2)

    
    - Roche SABCS materials:
      http://www.roche.com/media/events/med-sabcs2009.htm
    
    - More about Roche's work in oncology:
      http://www.roche.com/media_backgrounder/...
    
    - Oncology backgrounders:
      http://www.roche.com/media_backgrounder/...
    
    - Roche.com section on PHC:
      http://www.roche.com/research_and_develo...
    
    - http://www.thenewsmarket.com
    
    - Video clips and backgrounder on products:
      http://www.roche.com/med-cor-2009-05-15.htm

References ---------------------------------

[i] Baselga J. et al., Abstract 1004. American Society of Clinical Oncology Annual Meeting 2007.

[ii] Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002.

Roche Group Media Relations: Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com, Daniel Piller (Head), Alexander Klauser, Martina Rupp, Claudia Schmitt, Nina Schwab-Hautzinger

Contenido patrocinado